Shuxin Han | Molecular Mechanisms Signaling | Best Researcher Award

Published on by Cell Biologist

Dr. Shuxin Han | Molecular Mechanisms Signaling | Best Researcher Award

Dr. Shuxin Han | Xinjiang University | China

Dr. Shuxin Han is a distinguished molecular biologist and professor at Xinjiang University, widely recognized for his pioneering work in hepatobiliary and metabolic biology. With a research career spanning over two decades, Dr. Han has made major contributions to understanding how Kruppel-like factors, especially KLF15, regulate endobiotic and xenobiotic metabolism, impacting drug detoxification and metabolic disease mechanisms. He earned his Ph.D. from Kent State University and has held prestigious positions at Harvard Medical School and Case Western Reserve University. His groundbreaking studies have been published in high-impact journals like Nature Metabolism and Nature Communications, with several articles naming him as first or corresponding author. In addition to research, Dr. Han serves as a reviewer for top-tier journals in pharmacology, hepatology, and clinical science. He is also an academic leader, currently shaping the next generation of scientific talent and metabolic disease research in China.

Publication Profile: 

Scopus

Education:

Dr. Shuxin Han began his academic journey in Animal Sciences, earning a bachelor’s degree from Anhui Agricultural University (1994–1998). He advanced to a research assistant role at Peking University (1999–2000), where he deepened his scientific foundation. He then moved to the U.S. to pursue a Master’s in Biology at Temple University (2000–2003), followed by a Ph.D. in Molecular Biology from Kent State University (2004–2009), focusing on metabolic biology and gene regulation. This progression from general animal sciences to highly specialized molecular biology reflects a systematic and deep commitment to biomedical research. His strong academic preparation laid the foundation for a research career investigating how transcriptional regulators impact health and disease. Dr. Han’s training spans world-class institutions across both China and the United States, equipping him with diverse scientific perspectives and techniques.

Experience:

Dr. Shuxin Han has accumulated rich research and academic experience over nearly 30 years. His early career included a pivotal research assistant role at Peking University, followed by advanced training in biology and molecular biology at Temple and Kent State Universities. He completed prestigious postdoctoral training at Harvard Medical School (2009–2012) and Case Western Reserve University (2012–2015), where he later became a Senior Research Associate (2015–2019). He returned to China in 2019 as a Researcher at the University of Science and Technology of China First Affiliated Hospital, simultaneously engaging in academic duties at the university until 2023. Currently, he serves as a Professor and Academic Leader at Xinjiang University. Throughout his career, Dr. Han has built strong international collaborations, led research groups, and guided innovative projects in metabolic biology, demonstrating his leadership, research excellence, and academic mentorship capabilities.

Research Focus:

Dr. Shuxin Han’s research centers on the molecular regulation of metabolism, particularly focusing on the hepatobiliary and gastrointestinal systems. His work has elucidated the critical role of the Kruppel-like factor (KLF) family, especially KLF15, in controlling endobiotic and xenobiotic metabolism (EXM). These pathways govern how the body metabolizes both internal compounds and external substances like drugs. Dr. Han’s studies have shown that KLF15 acts as a master regulator, influencing drug resistance, liver injury, and metabolic homeostasis. His discoveries offer new insight into personalized medicine and treatment for metabolic disorders and drug-related toxicities. With numerous first-author and corresponding-author publications in journals such as Nature Metabolism, Nature Communications, and Drug Metabolism and Disposition, his work has significantly impacted both fundamental science and clinical applications. He is also active in peer-reviewing for top-tier journals and is recognized for his leadership in translational research.

Publications Top Notes:

  1. Unveiling KLF15 as the Key Regulator of Cyclosporine A Metabolism and Adverse Effects – Drug Metabolism and Disposition, 2025

  2. Distribution and Functional Significance of KLF15 in Mouse Cerebellum – Molecular Brain, 2025

  3. Personalized Statin Therapy: Targeting Metabolic Processes – Heliyon, 2025

  4. Current Status and New Directions for Hepatocellular Carcinoma Diagnosis – Liver Research, 2024

  5. KLF15-Cyp3a11 Axis Regulates Rifampicin-Induced Liver Injury – Drug Metabolism and Disposition, 2024

  6. Advancing Drug Delivery and Bioengineering in Liver Research – Bioengineering and Translational Medicine, 2024

  7. Advances in IL-7 Research on Tumor Therapy – Pharmaceuticals, 2024 (Co-author)

  8. Pathogenic Mechanisms in Alcoholic Liver Disease – Journal of Translational Medicine, 2023

  9. Beta-Hydroxybutyrate Effects on iPSC-Derived Cardiac Myocytes – Biomolecules, 2022

  10. Interactions Between Intestinal Flora and Bile Acids – International Journal of Molecular Sciences, 2022 (Corresponding author)

Conclusion:

In conclusion, Dr. Shuxin Han is a highly deserving candidate for the Best Researcher Award. His pioneering work on KLF15 and metabolic regulation has reshaped fundamental understanding in the field of hepatobiliary biology and pharmacology. His academic background, research productivity, international experience, and editorial service all reflect a well-rounded and impactful scientist. While there is room to increase clinical translation and international engagement, the depth, originality, and consistency of his research make him a strong contender for this recognition. Honoring Dr. Han with this award would acknowledge a career dedicated to scientific advancement with substantial implications for human health and drug therapy.

Lijuan Deng | Molecular Mechanisms Signaling | Molecular Cell Biology Award

Published on by Cell Biologist

Mrs. Lijuan Deng | Molecular Mechanisms Signaling | Molecular Cell Biology Award

Mrs. Lijuan Deng , Zhongshan Institute for Drug Discovery , China

Lijuan Deng is a passionate graduate student researcher at the Zhongshan Institute for Drug Discovery in China, specializing in the molecular mechanisms underlying metabolic diseases. Her scientific curiosity centers on gene regulation, signaling pathways, and metabolic dysregulation in disease progression, particularly metabolic-associated fatty liver disease (MASLD). Her translational approach blends experimental models and bioinformatics to bridge basic science and therapeutic innovation. Lijuan has already co-authored a publication in The FASEB Journal, identifying CDKN1A as a key regulator in MASLD. She is also the inventor of a patent-pending technique for nascent RNA labeling in extracellular vesicles. Through collaborations with clinical researchers and a solid foundation in molecular biology techniques, she is positioning herself as a rising talent in cell biology. Her work promises to advance understanding and treatment of metabolic diseases.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Innovative Research: Lijuan Deng has significantly contributed to the understanding of MASLD (Metabolic-Associated Steatotic Liver Disease) by identifying CDKN1A as a key regulatory gene through integrated transcriptomic analysis and experimental validation.

  2. Translational Focus: Her research bridges molecular biology and clinical application, enhancing its impact in drug discovery and disease diagnostics.

  3. Publication Record: She is the first author of a peer-reviewed article published in The FASEB Journal (SCI-indexed), showcasing her ability to conduct and communicate high-quality research.

  4. Patent Innovation: She holds a pending patent for a novel method involving nascent RNA labeling in extracellular vesicles, showing her drive toward technological advancement and biomedical innovation.

  5. Collaborative Approach: Active collaboration with the Department of Endocrinology at Shenzhen Second People’s Hospital reflects strong interdisciplinary and clinical integration.

🧩 Areas for Improvement:

  1. Expanded Publication Portfolio: Increasing the number of peer-reviewed articles will strengthen her academic visibility and impact.

  2. Professional Networking: Engagement in international cell biology societies or conferences and obtaining professional memberships can support broader recognition and growth.

  3. Editorial/Leadership Roles: Participation in editorial boards, review panels, or student leadership roles can enrich her professional development profile.

🎓 Education:

Lijuan Deng is currently pursuing her graduate studies in molecular biology at the Zhongshan Institute for Drug Discovery, where she focuses on translational biomedical research. Her academic foundation includes advanced coursework in biochemistry, molecular genetics, and cellular signaling. Through structured academic training, she has acquired proficiency in modern laboratory methods, including RNA sequencing, qPCR, western blotting, and exosome analysis. Her education emphasizes critical thinking and scientific rigor, enabling her to design experiments, analyze data, and interpret biological outcomes. She regularly participates in academic seminars, journal clubs, and collaborative workshops to refine her scientific acumen. Her thesis research is centered around identifying novel molecular targets in MASLD, a field gaining global relevance. Lijuan’s education is not only shaping her technical capabilities but also nurturing her ambition to contribute to impactful, real-world medical solutions through cell biology research.

💼 Experience:

Lijuan Deng has gained extensive laboratory experience as a graduate student researcher at the Zhongshan Institute for Drug Discovery. Her hands-on work includes both cellular and animal models, with a strong focus on metabolic disease mechanisms. She played a key role in identifying CDKN1A as a potential MASLD progression factor, combining transcriptomic data analysis with molecular validation. Additionally, she has worked on exosome-based biomarker discovery and developed a patent-pending method for nascent RNA labeling. She collaborates with the Department of Endocrinology at Shenzhen Second People’s Hospital, providing a clinical dimension to her work. Though early in her career, her contributions to translational research are already making an impact. She is skilled in molecular biology, gene expression profiling, and therapeutic target screening. Her research experience has been shaped by interdisciplinary collaboration, scientific publications, and the ambition to innovate within the field of molecular cell biology.

🧬 Research Focus:

Lijuan Deng’s research is primarily focused on the molecular underpinnings of metabolic-associated fatty liver disease (MASLD), a key manifestation of metabolic syndrome. She investigates how dysregulated genes, signaling networks, and lipid metabolism contribute to disease initiation and progression. A major highlight of her work is identifying CDKN1A as a potential risk factor in MASLD using integrated bioinformatics and experimental techniques. Additionally, she explores the utility of extracellular vesicles as carriers of diagnostic biomarkers and therapeutic molecules. Her patent-pending work involves a novel method for labeling nascent RNA within exosomes, opening possibilities for tracking dynamic RNA communication in disease contexts. Her research strategy merges molecular biology with disease modeling, aiming to bridge laboratory discoveries with potential therapeutic strategies. Through strong collaborations and a translational research outlook, Lijuan is dedicated to uncovering actionable insights that can inform drug development for complex metabolic disorders.

📚 Publications Top Notes:

  • 🧾 “Identification of CDKN1A as a potential key risk factor in MASLD progression.” – The FASEB Journal, 2025. DOI: 10.1096/fj.202402942R

🧾 Conclusion:

Lijuan Deng stands out as an emerging researcher with strong foundations in molecular cell biology and a clear orientation toward translational science. Her innovative work in MASLD, combined with an SCI publication and a pending patent, make her a highly suitable and promising candidate for the Molecular Cell Biology Award. While she is in the early stages of her career, her achievements thus far indicate substantial potential for future contributions to the field.